Aktienanalyse zu Relmada Therapeutics Inc (RLMD)RLMDRelmada Therapeutics Inc

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for central nervous system (CNS) and metabolic disorders. The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of CNS diseases and other disorders. The Company’s lead program, REL-1017, is a NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. Its lead product candidate, esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications. Sepranolone is its phase IIb ready neurosteroid developed for the potential treatment of Tourette syndrome and other compulsive disorders. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Relmada Therapeutics Inc (RLMD) is a good buy right now due to its current price of $3.27, which is significantly lower than the analyst price target of $12, indicating a potential upside of over 267%. Additionally, the stock's RSI is currently at 46.8, suggesting it is neither overbought nor oversold, which is favorable for new investors. The recent insider buying activity, with the CFO purchasing 200,000 shares at $4.22, reflects confidence in the company's future performance. However, the main risk is the company's negative earnings, with a projected EPS of -0.32 for Q2 2026, indicating ongoing financial challenges.